Publish Date: 10.09.2021
Category: News from the University
Researchers at the University of Ljubljana - Faculty of Medicine, University Medical Center, Celica Biomedical and the Blood Transfusion Center of the Republic of Slovenia have developed and clinically tested a new generation of autologous cell-based medicine for prostate cancer. The results showed that the survival of prostate cancer patients treated with autologous immunohybridomas (aHyC) prepared by fusion of dendritic and tumor cells correlated with a decrease in the subpopulation of natural killer cells in the peripheral blood, which has prognostic value.
Read more in our Research News.